DNA Script, Moderna Team Up For On-Demand Vaccines and Therapeutics For DARPA

by Vandana Singh, Benzinga Editor

April 27, 2021 10:33 AM | 1 min read | Make a Comment

DNA Script today announced a partnership with Moderna Inc MRNA to develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of the Defense Advanced Research Projects Agency's (DARPA) Nucleic Acids On-Demand World-Wide (NOW) Program.
The partnership will employ DNA Script's novel enzymatic synthesis platform to quickly generate high-fidelity nucleic acids without using hazardous chemical solvents to power Moderna's existing manufacturing technology for the rapid production of messenger RNA therapeutics and vaccines.
As part of the agreement, DNA Script will receive up to $5 million in grant funding from DARPA.
Price Action: MRNA shares are up 2.86% at $182.72 in the market trading session on the last check Tuesday.

Posted In: Biotech Government News Health Care Contracts General Briefs COVID-19 Vaccine

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.